Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor, in Children With Recurrent/Refractory Solid Tumors and Leukemias

What is the trial about?

To find out if MLN8237 can stop the tumor from growing or cause it to get smaller; To find out if MLN8237 can stop leukemia cells from growing or decrease the number of leukemia cells in the body.

Who can participate?

>12 months and < 21 yrs of age.

What is involved?

Length of study is 2 years. Standard cancer care including medical history; Physical exam; Blood tests; Urine tests; Pregnancy test; Scans of the tumor (CT, MRI or MIBG scans), bone marrow exam.

Contact Nemours Clinical Trials

Trial Name: A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor, in Children With Recurrent/Refractory Solid Tumors and Leukemias

COG#: ADVL0921

Contact Information

(800) 354-5690
clinicaltrials@nemours.org